NBDF is excited to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community.
The six webinars will be held on Zoom during the months of October, November, and December. Please note that these activities are free, but each webinar will require a separate registration.
The program will include the following topics and presenters-
October 21st
Update on Mimetics and Rebalancing Agents
Speaker: Professor David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario
October 28th
Update on Gene Therapy and Gene Editing
Speaker: Dr. Radoslaw Kaczmarek, Assistant Research Professor of Pediatrics, Gene and Cell Therapy Laboratory, Indiana University School of Medicine, Indiana.
November 18th
Update on Women and Girls with Bleeding Disorders
Speaker: Dr. Michelle Lavin, Consultant Haematologist, National Coagulation Centre, St. James's Hospital, Dublin. Chair, WFH.\, Women and Bleeding Disorders committee.
November 26th
Ageing and Haemophilia
Speaker: Professor Cedric Hermans, Head of Haemostasis and Thrombosis Unit Saint-Luc University Hospital, Brussels. WFH Vice President, Medical.
December 2nd
Importance of Patient Relevant Outcomes
Speaker: Mark Skinner, Institute of Policy Advancement. Chief investigator, PROBE study, Washington D.C.
December 9th
Update on Von Willebrand’s Disease
Speaker: Professor James O'Donnell, Consultant Haematologist, National Coagulation Centre, St. James's Hospital, Dublin. Director Institute of Vascular Biology, Royal College of Surgeons, Dublin.
All webinars will be held live at the following time-
6pm-7pm GMT // 7pm-8pm CET // 1pm-2pm EST
Visit the series homepage for more information and to register for these activities.
The IHS Clinical Webinar Series is supported by unrestricted educational grants from Novo Nordisk, CSL, and Roche.
